EQL Pharma AB (publ) (STO:EQL)
Sweden
· Delayed Price · Currency is SEK 55.50
+0.30 (0.54%)
At close: Mar 6, 2026
EQL Pharma AB Revenue
EQL Pharma AB had revenue of 118.90M SEK in the quarter ending December 31, 2025, with 28.93% growth. This brings the company's revenue in the last twelve months to 425.75M, up 25.81% year-over-year. In the fiscal year ending March 31, 2025, EQL Pharma AB had annual revenue of 373.52M with 41.39% growth.
Revenue (ttm)
425.75M
Revenue Growth
+25.81%
P/S Ratio
3.85
Revenue / Employee
7.74M
Employees
55
Market Cap
1.64B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 373.52M | 109.35M | 41.39% |
| Mar 31, 2024 | 264.17M | 4.26M | 1.64% |
| Mar 31, 2023 | 259.91M | -149.84M | -36.57% |
| Mar 31, 2022 | 409.75M | 230.61M | 128.73% |
| Mar 31, 2021 | 179.14M | 107.11M | 148.70% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Cereno Scientific AB | 44.27M |
| Orexo AB | 26.00M |
| Cinclus Pharma Holding AB | 57.47M |
| Nanexa AB | 55.94M |
| Dicot Pharma AB | 200.00K |
| Enzymatica AB | 53.90M |
| Moberg Pharma AB | 13.54M |
| BioGaia AB | 1.54B |